Literature DB >> 16019706

Mayo's Older African American Normative Studies: norms for the Mattis Dementia Rating Scale.

Laurie M Rilling1, John A Lucas, Robert J Ivnik, Glenn E Smith, Floyd B Willis, Tanis J Ferman, Ronald C Petersen, Neill R Graff-Radford.   

Abstract

Normative data are presented for older African Americans on the Mattis Dementia Rating Scale (DRS). These data were collected as part of Mayo's Older African Americans Normative Studies (MOAANS) in an effort to develop age-appropriate norms for African Americans elders on commonly used measures in neuropsychological assessment. In this study, the DRS was administered to 307 MOAANS participants ranging in age from 56 to 94 years. Age-corrected subtest and total scores were derived based on percentile ranks from actual frequency distributions across seven age ranges. Also presented is a regression-based computational formula that may be applied to the age-corrected DRS total score to further correct for years of education. These norms should help improve interpretation of DRS performance in African Americans and allow for greater diagnostic accuracy in patients with early cognitive decline.

Entities:  

Mesh:

Year:  2005        PMID: 16019706     DOI: 10.1080/13854040590945328

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  15 in total

1.  Group differences in normal neuropsychological test performance for older non-Hispanic White and Black/African American adults.

Authors:  Amy E Werry; Michael Daniel; Björn Bergström
Journal:  Neuropsychology       Date:  2019-07-25       Impact factor: 3.295

2.  Robust and expanded norms for the Dementia Rating Scale.

Authors:  Otto Pedraza; John A Lucas; Glenn E Smith; Ronald C Petersen; Neill R Graff-Radford; Robert J Ivnik
Journal:  Arch Clin Neuropsychol       Date:  2010-04-28       Impact factor: 2.813

Review 3.  Neuropsychological assessment of patients with dementing illness.

Authors:  Julie A Fields; Tanis J Ferman; Bradley F Boeve; Glenn E Smith
Journal:  Nat Rev Neurol       Date:  2011-11-01       Impact factor: 42.937

Review 4.  Race-norming of neuropsychological tests.

Authors:  Philip G Gasquoine
Journal:  Neuropsychol Rev       Date:  2009-03-19       Impact factor: 7.444

5.  Detecting dementia with the mini-mental state examination in highly educated individuals.

Authors:  Sid E O'Bryant; Joy D Humphreys; Glenn E Smith; Robert J Ivnik; Neill R Graff-Radford; Ronald C Petersen; John A Lucas
Journal:  Arch Neurol       Date:  2008-07

6.  Differential item functioning of the Boston Naming Test in cognitively normal African American and Caucasian older adults.

Authors:  Otto Pedraza; Neill R Graff-Radford; Glenn E Smith; Robert J Ivnik; Floyd B Willis; Ronald C Petersen; John A Lucas
Journal:  J Int Neuropsychol Soc       Date:  2009-07-02       Impact factor: 2.892

7.  Neuropsychological performance in advanced age: influences of demographic factors and Apolipoprotein E: findings from the Cache County Memory Study.

Authors:  Katheen A Welsh-Bohmer; Truls Ostbye; Linda Sanders; Carl F Pieper; Kathleen M Hayden; JoAnn T Tschanz; Maria C Norton
Journal:  Clin Neuropsychol       Date:  2008-06-10       Impact factor: 3.535

8.  Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Benjamin Mast; Kevin Duff; Tanis J Ferman; Irene Litvan
Journal:  Arch Clin Neuropsychol       Date:  2012-11-04       Impact factor: 2.813

9.  Challenges to the recognition and assessment of Alzheimer's disease in American Indians of the southwestern United States.

Authors:  Trudy Griffin-Pierce; Nina Silverberg; Donald Connor; Minnie Jim; Jill Peters; Alfred Kaszniak; Marwan N Sabbagh
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

10.  Behavioral abnormalities in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Kevin Duff; Benjamin Mast; Irene Litvan
Journal:  Psychiatry Res       Date:  2013-09-12       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.